Response Pharma Private Limited

Response Pharma Private Limited - trading in Kolkata, West Bengal, India. FY 2026 financials & compliance.
CIN U51909WB2017PTC220737 Incorporated 25 April 2017 ROC Kolkata HQ Kolkata, West Bengal, India
Active Private Limited Company trading MSME · Micro
Revenue · FY 2025
₹14.36 Lakh
▲ 40% YoY
Net loss · FY 2025
₹20,299
Net margin -1.4%
EBITDA · FY 2025
-₹20,299
EBITDA margin -1.4%
Authorised capital
₹5 Lakh
Registered with MCA
Paid-up capital
₹1 Lakh
Issued & subscribed
Company age
9 yrs
Est. 2017
Directors on board
3
As per MCA filings
Active GSTINs
1
GST registered

About Response Pharma Private Limited

Data last updated:

Response Pharma Private Limited is a private limited company based in Kolkata, West Bengal, India. It operates in the specialised services segment of the trading and commerce sector. It was incorporated on 25 April 2017 and has been in existence for over 9 years.

The company is registered with the Registrar of Companies (ROC), Kolkata, under CIN U51909WB2017PTC220737. Its GSTIN is 10AAICR2654L1ZD (Bihar).

The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors including Anjum Reza Jouher and Mohammad Afsar Alam.

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 31/1 Tiljala Road, Kolkata, West Bengal, India – 700046.

As per the financials filed for FY 2025, the company reported a revenue of ₹14.36 Lakh, a growth of 40% compared to the previous year. For the same year it recorded a net loss of ₹20,299 (net margin -1.4%) and EBITDA of -₹20,299 (EBITDA margin -1.4%). Revenue has declined at a compounded annual rate (CAGR) of 4% over three years.

Response Pharma Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-WB-10-0054122). The current compliance status is marked as compliant by the Registrar of Companies.

Company details

CIN U51909WB2017PTC220737
Registration Number 220737
Incorporation Date 25 April 2017
ROC Kolkata
Listing Status Unlisted
Company Status Active
Compliance Status Active Compliant
MSME Classification Micro
Udyam Registration UDYAM-WB-10-0054122

Recognitions & Rankings of Response Pharma

MSME (Udyam registered) Ministry of MSME
Category
Micro (2024-25)
Udyam number
UDYAM-WB-10-0054122

Contact details

Response Pharma Private Limited's registered office is in Kolkata, West Bengal. Its e-mail address is in the company report.

  • Email
  • Registered Address
    31/1 Tiljala Road, Kolkata, West Bengal, India – 700046
  • Industry
    Trading, Specialty, Wholesale

To see the full contact details of Response Pharma Private Limited, buy the company report.

Comprehensive company report
Response Pharma Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Business activity

The main business activity of Response Pharma is trade. In detail, this covers wholesale trading.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GTradeG1Wholesale Trading

To see the full business activity and turnover split of Response Pharma Private Limited, buy the company report.

Financials of Response Pharma Private Limited

FY 2025 filings available

Response Pharma Private Limited reported revenue of ₹14.36 Lakh (up 40% YoY) for FY 2025.

Revenue · FY 2025
₹14.36 Lakh ▲ 40%
Net loss · FY 2025
₹20,299 margin -1.4%
EBITDA · FY 2025
-₹20,299 margin -1.4%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 40%
3 years · compounded
▼ 4%
EBITDA CAGR growth
1 year
▲ 37%
3 years · compounded
▲ 51%
5 years · compounded
▲ 47%

Revenue rose 40% in the latest year, though over three years it has declined at a compounded annual rate (CAGR) of 4%. EBITDA rose 37% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA-₹20,299
Profit Before Tax
Tax Expense
Net Profit (PAT)-₹20,299
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin-1.4%
Net Profit Margin-1.4%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Response Pharma Private Limited, buy the company report.

Board of directors of Response Pharma Private Limited

Response Pharma has 3 directors on record. No former directors are listed.

Current Directors
NameDesignationAppointment DateTenureStatus
Anjum Reza JouherDirector25 Apr 20179 Years 6 MonthsCurrent
Mohammad Afsar AlamDirector25 Apr 20179 Years 6 MonthsCurrent
Abdullah SulaimanAdditional Director11 Dec 20250 Years 11 MonthsCurrent

Peer comparison

Response Pharma Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (wholesale trading), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Taaza Agro Products Marketing Company Pvt Ltd₹14.37 Lakh (FY 2024)-59.0%New Delhi, Delhi, India
Great Scientific Supplies Pvt. Ltd₹14.37 Lakh (FY 2021)-81.0%Mumbai, Maharashtra, India
Adonex Pharmaceutical Private Limited₹14.37 Lakh (FY 2023)-60.0%Ahmedabad, Gujarat, India
Avirvas Private Limited₹14.37 Lakh (FY 2025)-62.0%Darbhanga, Bihar, India
Aarnav Textile Mills Private Limited₹14.37 Lakh (FY 2021)-72.0%Ahmedabad, Gujarat, India
Response Pharma Private Limitedthis company₹14.36 Lakh (FY 2025)-₹20,299-1.4%40.0%Kolkata, West Bengal, India
Ramanujar Exim Private Limited₹14.36 Lakh (FY 2024)-24.0%Salem, Tamil Nadu, India
Emery Marketing Private Limited₹14.36 Lakh (FY 2025)-84.0%Kolkata, West Bengal, India
Best Deal General Trading Private Limited₹14.36 Lakh (FY 2017)75.0%New Delhi, Delhi, India
Pay 2 Lifestyle Private Limited₹14.35 Lakh (FY 2023)Siddharthnagar, Uttar Pradesh, India
Medzome Life Sciencez Private Limited₹14.35 Lakh (FY 2024)-58.0%New Delhi, Delhi, India

To see the full peer comparison of Response Pharma Private Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Response Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Response Pharma has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
10AAICR2654L1ZDBiharActive23 Dec 2017

To see the full GST registrations and return filing status of Response Pharma Private Limited, buy the company report.

Recent activity

Response Pharma Private Limited has 3 board changes on record since 2017: 3 appointments. The latest: Abdullah Sulaiman was appointed as Additional Director on 11 Dec 2025.

Appointed
Abdullah Sulaiman was appointed as Additional Director.
AGM
Response Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Response Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Kolkata I.
Appointed
Anjum Reza Jouher was appointed as Director.
Appointed
Mohammad Afsar Alam was appointed as Director.
Incorporation
25 Apr 2017
Response Pharma Private Limited was registered on 25 Apr 2017 with Roc Kolkata I & aged 9 years 6 months as per MCA records.

Frequently asked questions

Response Pharma is an active private limited company based in Kolkata, West Bengal, India. The company works in specialty, within the trading industry. It was incorporated on 25 April 2017 (9+ years old) and is registered under CIN U51909WB2017PTC220737.

Response Pharma has 3 current directors:

The latest financial statements of Response Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2018 are in the company report.

The GSTIN of Response Pharma is 10AAICR2654L1ZD, registered in Bihar.

The CIN (Corporate Identification Number) of Response Pharma is U51909WB2017PTC220737. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Response Pharma was incorporated on 25 April 2017, making it 9+ years old. It is registered with the Registrar of Companies, Kolkata.

The peers of Response Pharma by revenue are Taaza Agro Products Marketing Company Pvt Ltd, Great Scientific Supplies Pvt. Ltd, Adonex Pharmaceutical Private Limited, Avirvas Private Limited, Aarnav Textile Mills Private Limited and 5 more, all in the same principal business activity (wholesale trading).

Abdullah Sulaiman was appointed as Additional Director on 11 Dec 2025. Anjum Reza Jouher was appointed as Director on 25 Apr 2017. Mohammad Afsar Alam was appointed as Director on 25 Apr 2017.

Yes, Response Pharma is registered as a micro enterprise under Udyam registration (number: UDYAM-WB-10-0054122).

The registered office of Response Pharma is at 311 Tiljala Road, Kolkata, West Bengal, India – 700046.

Response Pharma operates in the trading industry, in the specialty segment.